| Adelina Roxana Buganu, MD | |
|
380 Hospital Dr, Macon, GA 31217-8001 | |
| (478) 751-0181 | |
| Not Available |
| Full Name | Adelina Roxana Buganu |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 380 Hospital Dr, Macon, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386209815 | NPI | - | NPPES |
| 0192593 | Other | MD | PARAMEDIC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 9999999999 (Georgia) | Primary |
| Entity Name | St Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700984622 PECOS PAC ID: 6709798333 Enrollment ID: O20040226000062 |
News Archive
AqueSys, Inc., a medical device company that develops, manufactures and distributes proprietary implants for glaucoma, today announced that it has secured $35 million in Series C financing. The round was led by Longitude Capital and Rho Ventures, with participation from existing investors Accuitive Medical Ventures, The Carlyle Group and SV Life Sciences.
Genzyme Corp. has announced that it has received approval to market Elaprase (idursulfase) in Japan for the treatment of Hunter syndrome.
A policy of single embryo transfer (SET) reduces the risk of perinatal mortality in infants born as a result of IVF and ICSI. The conclusion emerged from an analysis of more than 50,000 births recorded in the Australian and New Zealand Assisted Reproduction Technology Database between 2004 and 2008, where the introduction of an SET policy has been associated with a reduction in overall perinatal mortality for IVF and ICSI babies.
A research team from the Engelhardt Institute of Molecular Biology in Russia have shown that Nsp1 – a non-structured protein present in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen – stimulates translation termination in the stop codon recognition stage. Studying and developing drugs that compete with Nsp1 for binding with the termination complex could therefore be a potential strategy for fighting against coronavirus disease 2019 (COVID-19).
MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend its agreement with Merck KGaA, Darmstadt, Germany, for use of MDxHealth's MGMT assay in Merck KGaA's brain cancer clinical trials.
› Verified 8 days ago
| Entity Name | Gslpg, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366006702 PECOS PAC ID: 7810226875 Enrollment ID: O20190917001763 |
News Archive
AqueSys, Inc., a medical device company that develops, manufactures and distributes proprietary implants for glaucoma, today announced that it has secured $35 million in Series C financing. The round was led by Longitude Capital and Rho Ventures, with participation from existing investors Accuitive Medical Ventures, The Carlyle Group and SV Life Sciences.
Genzyme Corp. has announced that it has received approval to market Elaprase (idursulfase) in Japan for the treatment of Hunter syndrome.
A policy of single embryo transfer (SET) reduces the risk of perinatal mortality in infants born as a result of IVF and ICSI. The conclusion emerged from an analysis of more than 50,000 births recorded in the Australian and New Zealand Assisted Reproduction Technology Database between 2004 and 2008, where the introduction of an SET policy has been associated with a reduction in overall perinatal mortality for IVF and ICSI babies.
A research team from the Engelhardt Institute of Molecular Biology in Russia have shown that Nsp1 – a non-structured protein present in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen – stimulates translation termination in the stop codon recognition stage. Studying and developing drugs that compete with Nsp1 for binding with the termination complex could therefore be a potential strategy for fighting against coronavirus disease 2019 (COVID-19).
MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend its agreement with Merck KGaA, Darmstadt, Germany, for use of MDxHealth's MGMT assay in Merck KGaA's brain cancer clinical trials.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adelina Roxana Buganu, MD 3600 E Pratt St, Baltimore, MD 21224-2517 Ph: (240) 447-5634 | Adelina Roxana Buganu, MD 380 Hospital Dr, Macon, GA 31217-8001 Ph: (478) 751-0181 |
News Archive
AqueSys, Inc., a medical device company that develops, manufactures and distributes proprietary implants for glaucoma, today announced that it has secured $35 million in Series C financing. The round was led by Longitude Capital and Rho Ventures, with participation from existing investors Accuitive Medical Ventures, The Carlyle Group and SV Life Sciences.
Genzyme Corp. has announced that it has received approval to market Elaprase (idursulfase) in Japan for the treatment of Hunter syndrome.
A policy of single embryo transfer (SET) reduces the risk of perinatal mortality in infants born as a result of IVF and ICSI. The conclusion emerged from an analysis of more than 50,000 births recorded in the Australian and New Zealand Assisted Reproduction Technology Database between 2004 and 2008, where the introduction of an SET policy has been associated with a reduction in overall perinatal mortality for IVF and ICSI babies.
A research team from the Engelhardt Institute of Molecular Biology in Russia have shown that Nsp1 – a non-structured protein present in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen – stimulates translation termination in the stop codon recognition stage. Studying and developing drugs that compete with Nsp1 for binding with the termination complex could therefore be a potential strategy for fighting against coronavirus disease 2019 (COVID-19).
MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend its agreement with Merck KGaA, Darmstadt, Germany, for use of MDxHealth's MGMT assay in Merck KGaA's brain cancer clinical trials.
› Verified 8 days ago
Dr. Allison Harriott, MD MPH Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 350 Hospital Dr, Macon, GA 31217 Phone: 478-765-7000 | |
Dr. Philip Enrique Chung, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1550 College St, Macon, GA 31207 Phone: 678-790-0729 | |
Lisa Kirkland, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 350 Hospital Dr, Macon, GA 31217 Phone: 770-994-9326 Fax: 770-994-4747 | |
Lloyd Harrington, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 777 Hemlock St, Msc 10, Macon, GA 31201 Phone: 478-633-7707 | |
Rao Chapala, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 400 Charter Blvd Medical Building, Macon, GA 31210 Phone: 478-756-6131 | |
Nalini Ramaiya, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2410 Ingleside Ave, Macon, GA 31204 Phone: 478-845-7462 Fax: 855-791-3372 | |
Dr. Matthew Raymond Astin, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 777 Hemlock St, Macon, GA 31201 Phone: 478-633-7707 |